By suppressing the tumor suppressor TCEAL7, exo-miR-301a contributes to therapeutic resistance, positioning the exo-miR-301a/TCEAL7 axis as a key target in GBM treatment [93]. This evidence concerns the gene TCEAL7 and neoplasm.